Abstract：ObjectiveTo investigate the clinical effect of Entecavir combined with Fuzheng Huayu Tablets in the treatment of decompensated hepatitis B patients.MethodsThe clinical data of 78 patients with decompensated hepatitis B from June 2015 to May 2016 in our hospital were retrospectively analyzed.The patients were divided into two groups(n=39)by random number table method.The patients in the control group were treated with Entecavir Dispersible Tablets.The patients in the treatment group were treated with Fuzheng Huayu Tablets on the basis of the control group.Both groups were treated for 1 year and were followed up for 3 months.The liver function indexes and serum liver fibrosis indexes were measured before and after treatment in both groups.The diameter of main portal vein and the spleen thickness before and after treatment were observed with abdominal ultrasonography.FibroScan was used to measure and record the liver cirrhosis(Stiffne value)before and after treatment.The negative rate of HBeAg and HBV DNA in both groups were calculated.The Child-Pugh scores and adverse reactions were compared between the two groups after treatment.ResultsThe indexes of ALT,AST,TBil,ALB and other indexes of serum liver fibrosis of HA,LN,PCⅢandⅣ-C in two groups after 1 year of treatment and 3 months of follow-up were significantly lower than those in the control group(P<0.05).After treatment,the above indexes in the treatment group were significantly better than those in the control group(P<0.05).The other two groups were significantly better than the treatment group before significantly reduced after treatment,the treatment group improved significantly better than the control group(P<0.05).The negative conversion rate of HBV DNA after treatment in treatment group was 89.74%,66.67%in control group,and Child-Pugh score was significantly lower than that in control group,the differences were statistically significant(P<0.05).But there was no statistical difference in the negative conversion rate of HBeAg between the two groups(P＞0.05).During the treament and after treatment of two groups,no serious adverse reactions occurred.ConclusionEntecavir combined with Fuzhenghuayu can significantly improve liver function in patients with decompensated hepatitis B and effectively inhibit or even reverse the progress of liver fibrosis.Compared with Entecavir alone,the clinical efficacy is better and the prognosis is more stable,which is worthy of clinical application.
京公网安备 11010502046607号